Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DML8S0W)

Drug Name
MEDI6570 Drug Info
Indication
Disease Entry ICD 11 Status REF
Cardiovascular disease BA00-BE2Z Phase 2 [1]
Coronary heart disease BA80.Z Phase 2 [1]
Cross-matching ID
TTD Drug ID
DML8S0W

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Lectin-like oxidized LDL receptor (OLR1) TTKSND3 OLR1_HUMAN Modulator [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Lectin-like oxidized LDL receptor (OLR1) DTT OLR1 4.995 4.194 5.326 4.129
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Cardiovascular disease
ICD Disease Classification BA00-BE2Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Lectin-like oxidized LDL receptor (OLR1) DTT OLR1 3.35E-01 -0.08 -0.35
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04610892) A Phase IIB, Randomized, Double Blinded, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of MEDI6570 in Participants With a Prior Myocardial Infarction and Persistent Inflammation. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of AstraZeneca